Synthetic studies of salinosporamide A through the intramolecular hydroamidation of alkynes by Kamisaki, Haruhi et al.
Title Synthetic studies of salinosporamide A through theintramolecular hydroamidation of alkynes
Author(s)Kamisaki, Haruhi; Kobayashi, Yusuke; Kimachi, Tetsutaro;Yasui, Yoshizumi; Takemoto, Yoshiji
CitationJ urnal of Organometallic Chemistry (2011), 696(1): 42-45
Issue Date2011-01
URL http://hdl.handle.net/2433/134562



















Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida, Sakyo-ku, Kyoto 606-8501, 
Japan. 
2
 Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo 
663-8179, Japan. 
3 
World Premier International Research Center, Advanced Institute for Materials 
Research, Tohoku University, Aoba, Sendai 980-8578, Japan. 
 
Corresponding author. Tel.: +81 75 753 4528; fax: +81 75 753 4569. E-mail address: 
takemoto@pharm.kyoto-u.ac.jp (Y. Takemoto).  
 
Abstract: 
Rhodium-catalyzed intramolecular hydroamidation of alkynes was carried out to construct the synthetic 
intermediates of a proteasome inhibitor, salinosporamide A. Several alkynyl formamides were 
synthesized and subjected to the hydroamidation reaction. Some derivatives with a methoxymethyl 
(MOM) or 2-methoxy-2-propyl (MOP) group near the reaction site were converted to the corresponding 





The synthesis of salinosporamide A (1) [1], a potent and selective proteasome inhibitor, has attracted 
much interest due to its important bioactivity and polysubstituted lactam structure [24]. In connection 
with our research on the synthesis of functionalized lactams through transition-metal-catalyzed reactions 
[5], we have launched a program directed toward the total synthesis of salinosporamide A. Our plan is 
based on the transition-metal-catalyzed hydroamidation of alkynes. By applying this reaction 
intramolecularly, we previously showed that -alkylidene--lactams can be synthesized from alkynyl 
formamides (Scheme 1) [6]. This approach has advantages for the synthesis of functionalized lactams in 
terms of ready access to cyclization precursors and neutral reaction conditions. Preceding studies [7] on 
hydroamidation were limited to simple substrates, and the reaction has rarely been applied to natural 

















Our retrosynthetic analysis is shown in Scheme 2. To examine the key intramolecular hydroamidation, 
four cyclization precursors (3, 7, 11, and 14) were designed. The targeted salinosporamide A (1) could be 
simplified by removing the cyclohexene moiety, opening the -lactone, and introducing the exo-double 
bond in the lactam ring to yield -lactam 2. This compound was envisioned to be formed by a key 
intramolecular hydroamidation that requires alkynyl formamide 3 as a precursor. Compound 3 could be 
obtained by the alkynylation of keto amide 4. Oxidation of known amino alcohol 5 [3a] derived from 
threonine will give ketone 4. Formamide 7, a cyclization precursor which lacks a methyl group at the 
propargylic position, could be prepared via synthetic intermediates 8 and 9 by a sequence similar to that 
for 3 from serine. Comparison of the hydroamidation of 7 with that of 3 may reveal the effect of steric 
hindrance near the alkynyl group. Another substrate for hydroamidation is acetal 11 which could be 
obtained from aldehyde 12. For the total synthesis, differentiation of the two diastereotopic alkoxy groups 
in the acetal moiety of 10 is required after the hydroamidation of 11. We were also interested in 
formamide 14 with a simple alkyl group instead of a siloxymethyl group on the alkyne, since the 























































































2. Results and discussion 
 
The synthesis of 3 was attempted from amino alcohol 5 obtained from threonine through oxazoline 15 
[3a] (Scheme 3). Alcohol 5 was converted to keto formamide 4 by formylation and oxidation. However, 
the alkynylation of 4 did not proceed despite numerous and varied attempts; therefore, the cyclization 


































On the other hand, the syntheses of 7a-d, 7a’, and 7d’ were feasible (Scheme 4). Similar to 4, aldehyde 8 
was obtained in four steps from serine via 16 [10] and 9. Addition of the lithium acetylide gave the 
desired alkynyl formamide as a 1:2 mixture of diastereomers, 7a (less polar) and 7a' (polar). During this 
addition process, the formation of retro-aldol product 17 was observed. This causes a moderate yield of 7. 
Through appropriate protection of the hydroxy group in 7a and 7a', formamides 7b-d and 7d’ were 
obtained (7b: R
2
 = Ac, 7c: R
2
 = TES, 7d and 7d': R
2





































































Formamides 11a-d and 14a were synthesized in a straightforward manner (Scheme 5). Acetalization [11] 
of triol 18 followed by benzylation gave amino alcohol 19. Selective N-formylation of this amino alcohol 
was accomplished with ethyl formate and sodium hydride in EtOH. Subsequent Swern oxidation gave 
aldehyde 12, which was subjected to alkynylation with lithiated 3-siloxy-1-propyne or 1-butyne. 
Quenching of the alkoxides in situ with electrophiles such as water, TESCl, and MOMCl gave the 






































11a (R2= H, R3=CH2OTBS)
11b (R2= TES, R3=CH2OTBS)
11c (R2= MOM, R3=CH2OTBS)







11d (R2= MOP, R3=CH2OTBS)  
Scheme 5. 
 
Hydroamidation was performed with Rh4(CO)12 (20 mol %) in xylene at 130 
o
C (Table 1) [6]. When 7a 
with a free hydroxy group was subjected to the reaction, -lactam 6a was obtained in 36% yield (entry 1). 
A significant amount of compound 17 (see Scheme 4) was also isolated (56%), which was probably 
formed by retro-aldol fragmentation. The corresponding diastereomer 7a' gave similar results, which 
indicates that the stereochemistry at the propargylic position does not affect the reaction (entry 2). The 
same reaction of acetate 7b and silyl ether 7c did not give good results (entries 3, 4). However, 
2-methoxy-2-propyl (MOP) derivatives 7d and 7d' underwent hydroamidation to give lactams 6a and 6a’ 
in high yields after unexpected cleavage of the MOP group (entries 5, 6). It is likely that the MOP group 
was cleaved after cyclization because of the clear difference between the yields of entries 1 and 5. The 
reaction was also insensitive to the configuration of the starting materials 7d and 7d'. Similarly, 
hydroxy-free acetal 11a gave lactam 10a in 30% yield (entry 7). The reaction of 11b (R
2 
= TES) was also 
unsatisfactory (entry 8). Although the MOP group was cleaved during the reaction, compounds 11c and 
11d with either a MOM or MOP group were converted to the corresponding lactams in acceptable yields 
(entries 9, 10). Since treatment of MOM 14 bearing an ethyl group instead of a siloxymethyl group under 
the same conditions furnished the desired product 13a in a yield comparable to that of 11c (entry 11), the 
acetylene can accommodate a simple alkyl group as an R
3
 substituent. The results in Table 1 show that 
substrates with acetal moieties such as MOM or MOP at the propargylic position gave better yields than 
others. The origin of this effect is under investigation in our laboratories. 
 
 






































entry substrate product yield (%)b 
1 7a (R2 = H) 6a (R2 = H) 36 c 
2 7a' (R2 = H) 6a' (R2 = H) 24 d 
3 7b (R2 = Ac) 6b (R2 = Ac) - 
4 7c (R2 = TES) 6c (R2 = TES) 18 (53) 
5 7d (R2 = MOP) 6a (R2 = H) quant 
6 7d' (R2 = MOP) 6a' (R2 = H) 92 
7 11a (R2 = H, R3 = CH2OTBS) 10a (R
2 = H, R3 = CH2OTBS) 30 
8 11b (R2 = TES, R3 = CH2OTBS) 10b (R
2 = TES, R3 = CH2OTBS) 29 (22) 
9 11c (R2 = MOM, R3 = CH2OTBS) 10c (R
2 = MOM, R3 = CH2OTBS) 61 
10e 11d (R2 = MOP, R3 = CH2OTBS) 10a (R
2 = H, R3 = CH2OTBS) 48 
11 14a (R2 = MOM, R3 = Et) 13a (R2 = MOM, R3 = Et) 59 
a Reaction was carried out with Rh4(CO)12 (20 mol %) in xylene at 130 
oC for 2 h. b The values in parentheses show the yield of 
recovered starting materials. c Compound 17 (see Scheme 4) was isolated in 56% yield. d Compound 17 was isolated in 70% yield. 
e 10 mol% of the catalyst was used. 
 
In summary, we have developed concise synthetic routes to the key intermediates of salinosporamide A 
and its analogs. Hydroamidation was shown to be feasible even for functionalized substrates. It is worth 
noting that during the synthesis, the formyl group which initially acted as a protecting group, was 
incorporated into the molecular framework by its chemoselective activation with the rhodium catalyst. 
The results described herein are a progressive attempt to apply hydroamidation to total synthesis. 
Chemoselective activation of an inert functionality such as formamide with a transition metal catalyst was 
shown to be an effective and attractive synthetic strategy in a multistep synthesis. Further investigations 





3.1. General procedure for rhodium-catalyzed intramolecular hydroamidation 
 
A mixture of formamide (0.0252 mmol) and Rh4(CO)12 (3.77 mg, 0.00504 mmol) in xylene (0.25 ml) was 
stirred at 130 
o
C for 2 h under Ar atmosphere. After cooling and evaporation of the volatile materials, the 
crude residue was purified by SiO2 column chromatography to give lactam. 
 
3.1.1 Analytical data for lactam 6a 1H NMR (500 MHz, CDCl3, ) 7.34–7.30 (m, 4H), 7.18–7.15 (m, 4H), 
6.76 (d, 1H, J = 8.6 Hz), 6.74 (ddd, 1H, J1 = J2 = 4.8 Hz, J3 = 2.1 Hz), 5.03 (dd, 1H, J1 = 6.7 Hz, J2 = 2.1 
Hz), 4.62 (d, 1H, J = 15.3 Hz), 4.54 (dd, 1H, J1 = 4.8 Hz, J2 = 1.5 Hz), 4.53 (dd, 1H, J1 = 4.8 Hz, J2 = 1.5 
Hz), 4.47 (d, 1H, J = 15.3 Hz), 4.27 (d, 1H, J = 11.9 Hz), 4.21 (d, 1H, J = 11.9 Hz), 3.87 (d, 1H, J = 10.4 
Hz), 3.85 (d, 1H, J = 10.4 Hz), 3.76 (s, 3H), 3.54 (s, 3H), 3.45 (d, 1H, J = 6.7 Hz), 0.91 (s, 9H), 0.11 (s, 
6H); 
13
C NMR (126 MHz, CDCl3, ) 171.1, 167.8, 158.8, 137.3, 136.5, 133.1, 129.6, 128.6, 128.5, 127.9, 





) 555.2652. Found 555.2657. 
 
3.1.2 Analytical data for lactam 6a’  
1
H NMR (500 MHz, CDCl3, ) 7.34–7.31 (m, 3H), 7.21 (d, 2H, J = 7.0 Hz), 7.16 (d, 1H, J = 8.6 Hz), 6.74 
(d, 2H, J = 8.6 Hz), 6.64 (dd, 1H, J1 = 6.4 Hz, J2 = 3.1 Hz), 5.11 (m, 1H), 4.63–4.52 (m, 3H), 4.39–4.30 
(m, 3H), 3.90 (d, 1H, J = 10.7 Hz), 3.82 (d, 1H, J = 10.7 Hz), 3.74 (s, 3H), 3.39 (s, 3H), 0.91 (s, 9H), 0.13 
(s, 3H), 0.13 (s, 3H); 
13
C NMR (126 MHz, CDCl3, ) 169.8, 168.6, 158.9, 137.5, 134.0, 132.8, 130.3, 
128.8, 128.4, 127.9, 127.8, 113.5, 73.2, 71.4, 69.4, 66.6, 62.3, 55.2, 52.0, 44.3, 25.8, 18.4, –0.1, –5.7; IR 






) 556.2731. Found 556.2731. 
 
3.1.3 Analytical data for lactam 10c 
1
H NMR (500 MHz, CDCl3, ) 7.25 (d, 2H, J = 8.8 Hz), 6.88 (dd, 1H, J1 = J2 = 6.4 Hz), 6.84 (d, 2H, J = 
8.8 Hz), 4.84 (s, 1H), 4.65 (s, 2H), 4.56 (d, 2H, J = 5.2 Hz), 4.06 (d, 1H, J = 12.2 Hz), 3.93 (d, 1H, J = 
12.2 Hz), 3.79 (s, 3H), 3.53 (d, 1H, J = 11.9 Hz), 3.38 (s, 3H), 3.10 (d, 1H, J = 11.9 Hz), 1.36 (s, 6H), 
0.92 (s, 9H), 0.10 (s, 3H), 0.098 (s, 3H); 
13
C NMR (126 MHz, CDCl3, ) 168.0, 159.1, 139.4, 128.9, 







) 521.2809. Found 521.2789. 
 
3.1.4 Analytical data for lactam 13a 
1
H NMR (500 MHz, CDCl3, ) 7.25 (d, 2H, J = 8.9 Hz), 6.84 (d, 2H, J = 8.9 Hz), 6.83 (t, 1H, J = 14.7 
Hz), 4.83 (s, 1H), 4.66 (s, 2H), 4.55 (s, 2H), 4.09 (d, 1H, J = 12.2 Hz), 3.94 (d, 1H, J = 12.2 Hz), 3.79 (s, 
3H), 3.53 (d, 1H, J = 12.2 Hz), 3.41 (s, 3H), 3.07 (d, 1H, J = 12.2 Hz), 2.40 (dq, 2H, J1 = 14.7 Hz, J2 = 
7.4 Hz), 1.37 (s, 3H), 1.36 (s, 3H), 1.01 (t, 3H, J = 7.4 Hz); 
13
C NMR (126 MHz, CDCl3, ) 168.4, 159.0, 
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